The city of Boston, Massachusetts, currently has 459 active clinical trials seeking participants for Cancer research studies.
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT03990896
Recruiting
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
NCT06202183
Recruiting
This research study is a randomized controlled trial that will observe changes in microbiome activity, changes in chemotherapy toxicity, and any changes in treatment outcomes between two groups of participants undergoing chemotherapy with either early-stage or metastatic colorectal cancer. The names of the study groups involved in this study are: * Exercise * Waitlist Control
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/22/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Colorectal Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer
Register for Updates
Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2024
Locations: SystImmune Recruiting Site, Boston, Massachusetts
Conditions: Non Small Cell Lung Cancer, NSCLC, Lung Cancer, Breast Cancer, Esophageal Cancer, SCLC, Small Cell Lung Cancer, NPC, Nasopharyngeal Cancer
Register for Updates
CV CARE: CardioVascular Care in PC Patients
NCT06202820
Recruiting
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants. The name of the intervention used in this research study is: CV Care (cardiovascular risk assessment and management program)
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/19/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Prostate Cancer, Cardiovascular Diseases
Register for Updates
Study to Evaluate CCS1477 in Advanced Tumours
NCT03568656
Recruiting
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Metastatic Castration-Resistant Prostate Cancer, Advanced Solid Tumors, Metastatic Breast Cancer, Non-small Cell Lung Cancer
Register for Updates
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
NCT05271292
Recruiting
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2024
Locations: Dana Farber Cancer Institue, Boston, Massachusetts
Conditions: Advanced Solid Malignant Tumor, Small Cell Lung Cancer
Register for Updates
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT04839614
Recruiting
To assess the feasibility of an expedited referral process for the obese endometrial cancer or EIN patient from her gynecologic oncologist to the Brigham Center for Metabolic and Bariatric Surgery (CMBS) in order to undergo concurrent weight loss surgery and hysterectomy within 8 weeks of first appointment with a gynecologic oncologist (or 12 weeks for EIN patients).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/15/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Endometrial Carcinoma, Obesity, EIN, Endometrial Intraepithelial Neoplasia, Endometrial Cancer Stage I
Register for Updates
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352
Recruiting
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Endometrial Cancer
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +4 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
SIRT With Tremelimumab and Durvalumab for Resectable HCC
NCT05701488
Recruiting
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
Register for Updates
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
NCT05327452
Recruiting
The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispanic breast, colorectal, or prostate cancer patients. The names of the study interventions involved in this study are: * Supervised aerobic and resistance exercise (SUP) - virtually supervised 16- week aerobic and resistance exercise performed at home via Zoom. * Unsupervised aerobic and resistance exercise (UNSUP) - ho... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, Colorectal Cancer, Prostate Cancer
Register for Updates
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT04150042
Recruiting
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic cancer in patients who have a deleterious or suspected deleterious BRCA1, BRCA2, or PALB2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. A dose-escalation schedule will be employed fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Breast Cancer Metastatic, Breast Cancer Stage IV, Pancreatic Cancer Stage IV, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Adenocarcinoma of the Breast, PALB2 Gene Mutation
Register for Updates